Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer - European Medical Journal

Continue

Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer

Oncology
At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim analysis of a phase 2, randomised, open-label, parallel group clinical trial of TAK-385, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of patients with advanced prostate cancer.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.